Search
forLearn
5 / 801 resultslearn PTD-DBM
learn TeraCeutic™
learn trimethicone
learn medium chain triglycerides
Research
5 / 1000+ results
research SAT-358 Hypercalcemia-Induced Altered Mental Status as the Primary Manifestation of Classic Hodgkin Lymphoma
An 87-year-old man showed unusual signs of Hodgkin lymphoma, primarily high calcium levels, which improved after treatment and revealed the disease.
research Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
Targeting multiple pathways and understanding genetic mutations are crucial for effective melanoma therapy.
research The Tumor Suppressor Actions of the Vitamin D Receptor in Skin
Vitamin D receptor helps prevent skin tumors.
research Phase I Clinical Testing Antimalarial Drugs.
Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.
research Cutaneous complications of chemotherapeutic agents
Chemotherapy can cause skin problems like hair loss, mouth sores, and skin darkening, and recognizing these can affect treatment decisions.
Community Join
5 / 1000+ resultscommunity Kintor's email response to me, regarding false advertising, and my proposal for them to develop a topical dut formulation with meaningful efficacy.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
community Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Possible solution: 2.5mg DUT for everyone
A user is experimenting with creating a DIY oral Dutasteride solution using raw powder, MCT oil, and Vitamin E to reduce costs. Others discuss their experiences with similar methods and the challenges of sourcing and testing Dutasteride.